Capital Fund Management S.A. Vertex Pharmaceuticals Inc Call Options Transaction History

Capital Fund Management S.A.

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $5.92 Million - $6.34 Million	17,500 New	17,500 $6.09 Million
Q4 2022 Feb 13, 2023	SELL	$285.76 - $321.48 $2.34 Million - $2.64 Million	-8,200 Reduced 35.81%	14,700 $4.25 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $6.27 Million - $7 Million	22,900 New	22,900 $6.63 Billion
Q1 2020 May 13, 2020	BUY	$199.77 - $247.81 $2.02 Million - $2.5 Million	10,100 Added 631.25%	11,700 $2.78 Million
Q4 2019 Feb 13, 2020	SELL	$166.71 - $223.91 $216,723 - $291,083	-1,300 Reduced 44.83%	1,600 $350,000
Q4 2017 Feb 09, 2018	SELL	$137.28 - $155.55 $356,928 - $404,430	-2,600 Reduced 47.27%	2,900 $435,000
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $814,715 - $892,320	5,500	5,500 $836,000

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.